September 14-16 | New York, USA

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will attend the Morgan Stanley 24th Annual Global Healthcare Conference in New York from September 14 to 16.

September 14-16 | Riyadh, Saudi Arabia

Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026 from September 14 to 16.

September 17-19 | Shanghai, China

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the Bio-Shanghai Week 2026. On September 17 at 3:00 PM.

September 18 | Boston, USA

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the Harvard IvyTech Discussion on September 18.

Consensus recommendations for treating patients aged 80 and over in intensive care were developed by an international expert panel. Researchers re-examined the panel's 128 responses to ask whether a clinician's gender shaped how they rated the proposed recommendations. For most, it did not. 

A new collaborative study reveals how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels. By tracking germinal-center activity and individual secreted antibody clonotypes for up to six months, researchers uncover how vaccination drives the evolution and diversification of immune responses. The findings offer new insights into how mRNA technology could help address a key challenge in influenza prevention: generating broader antibody responses against a constantly evolving virus.

Using advanced nuclear magnetic resonance (NMR) spectroscopy and clinical expertise in transfusion medicine, the Canadian team identified a hidden mechanism that controls whether a blood protein remains harmless or becomes the target of clot-causing antibodies.

Risk factors for cardiovascular-kidney-metabolic disease, a health condition made up of heart disease, kidney disease, diabetes, and obesity, can be identified in children as young as 8, UTHealth Houston researchers discovered. 

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults.